Press­ing for di­rect ne­go­ti­a­tions, Take­da adds cash to a meati­er $63B bid to buy Shire

8 years ago
Deals

Hong Kong clears way for pre-rev­enue biotech IPOs, plans to ac­cept list­ing ap­pli­ca­tions by May

8 years ago
Financing
China

Arc­turus takes an­oth­er le­gal stab at for­mer CEO as pub­lic bat­tle turns se­ri­ous for the com­pa­ny

8 years ago
People
Pharma

John Or­win tapped to lead Atre­ca; John Tsai takes Vas Narasimhan's old role at No­var­tis; Hal Bar­ron nabs Genen­tech's ...

8 years ago
Peer Review

No­var­tis CEO Vas Narasimhan is rais­ing the bar on sec­ond-gen can­cer drug stud­ies

8 years ago
R&D
Pharma

With Gilenya gener­ics loom­ing, No­var­tis’ sipon­i­mod team buffs up the MS da­ta pack­age be­ing prepped for the FDA

8 years ago
R&D

CHMP scolds AB Sci­ence (again) for ma­sitinib short­com­ings, trig­ger­ing a new rout on stock price

8 years ago
Pharma

UCB snags an NDA-ready epilep­sy drug from Prox­im­a­gen in $370M deal

8 years ago
Pharma

Bio­gen pays $1B cash to en­list Io­n­is on a new drug dis­cov­ery cam­paign — but can it de­liv­er fast enough for ...

8 years ago
R&D
Pharma

On sec­ond thought, Al­ler­gan does­n't want to con­sid­er a bid for Shire, leav­ing Take­da in sole pur­suit of $62.5B deal

8 years ago
Deals

GW Phar­ma walks away from ad­comm with unan­i­mous sup­port for an­ti-seizure med. An OK shouldn’t take long now

8 years ago
Pharma

Toca­gen li­cens­es im­munother­a­py to Apol­lo­Bio for $16M up­front; WuXi AppTec un­veils ex­pand­ed lab test­ing site in New ...

8 years ago
News Briefing

Biotech uni­corn's 'brain' at­tracts a $115M mega-round as in­vestors em­brace AI up­start

8 years ago
Financing
AI

In knock­out IPO of­fer­ings, Mor­phoSys and Sur­face On­col­o­gy haul com­bined $316M in up­sized deals

8 years ago
Financing

Bid­ding war erupts for Shire as Take­da is stiff-armed on a $62.5B of­fer and Al­ler­gan jumps in

8 years ago
Deals

FDA’s in­sid­er re­view rais­es se­ri­ous safe­ty is­sues as Eli Lil­ly’s quick come­back shot for baric­i­tinib heads for ...

8 years ago
Pharma

Klein­er Perkins’ Beth Sei­den­berg bumps Tmu­ni­ty’s cell ther­a­py round to a cool $135M

8 years ago
Financing

Badrul Chowd­hury jumps ship at the FDA and moves to As­traZeneca, join­ing an ex­o­dus of agency of­fi­cials

8 years ago
People
Pharma

No­var­tis poach­es Bris­tol-My­ers/Am­gen vet John Tsai for top drug de­vel­op­ment post in a $9B or­ga­ni­za­tion

8 years ago
People
R&D

As­traZeneca wins ex­pand­ed OK to use Tagris­so in front­line lung can­cer niche, spurring hope of hit­ting $3B sales goal

8 years ago
Pharma

Blue­bird’s gene ther­a­py for be­ta-tha­lassemia falls short of a cure, but still wows in 22 pa­tients

8 years ago
R&D
Cell/Gene Tx

Full FDA let­ter in hand, Sol­id Bio says it's work­ing to re­verse clin­i­cal hold on its DMD gene ther­a­py

8 years ago
R&D
Cell/Gene Tx

Sanofi CFO Jerome Con­t­a­mine hits the ex­it; Strug­gling Fi­bro­cell trig­gers a strate­gic re­view

8 years ago
News Briefing

Glax­o­SmithK­line’s Hal Bar­ron poach­es Genen­tech’s top can­cer drug deal­mak­er for his new R&D team

8 years ago
People
R&D
First page Previous page 1034103510361037103810391040 Next page Last page
A service from the Financial Times